Eric Winer, MD

Dr. Eric Winer was appointed Director of Yale Cancer Center and President and Physician-in-Chief of Smilow Cancer Hospital Yale New Haven Health System on February 1, 2022. He is also the Alfred Gilman Professor of Medicine and Pharmacology and Deputy Dean of Cancer Research at Yale School of Medicine. An internationally renowned expert in breast cancer, Dr. Winer has led and collaborated on innumerable clinical trials that have changed the face of the disease. His work has touched almost all aspects of breast cancer and he is particularly well known for his work in HER2 positive disease. Dr. Winer has long been an advocate of building teams consisting of scientists and clinicians to accelerate progress in cancer research and care. He previously served as principal investigator of a breast cancer Specialized Program of Research Excellence (SPORE) for over a decade.

Dr. Winer is a member of the Board for the American Society of Clinical Oncology (ASCO) and a member of the Scientific Advisory Board of the Breast Cancer Research Foundation. For over a decade, he served as chief scientific advisor and chair of the Scientific Advisory Board for Susan G. Komen for the Cure. He co-led the National Cancer Institute Breast Cancer Steering Committee from 2016-2022. Dr. Winer has published over 400 original manuscripts and mentored over 30 fellows and junior faculty. In recognition of his mentoring impact, he was the recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School in 2020. He has also received numerous awards for his breast cancer research, most notably the William L. McGuire Memorial Lecture Award in 2016 at the San Antonio Breast Cancer Symposium, the Gianni Bonadonna Breast Cancer Award at ASCO in 2017, the Susan G. Komen Brinker Award for Clinical Research in 2018, and the Jill Rose award from the Breast Cancer Research Foundation in 2019.

Dr. Winer is an alumnus of both Yale College and Yale School of Medicine. After receiving his medical degree in 1983, he completed training in internal medicine and served as chief resident at Yale New Haven Hospital. He completed a fellowship in hematology/oncology at Duke University School of Medicine and served on the Duke faculty from 1989 to 1997. He then joined Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School where he built an internationally prominent breast cancer program. Prior to his move back to Yale in 2022, he held the Thompson Chair in Breast Cancer Research and served as chief clinical development officer, and senior vice president for medical affairs at Dana-Farber Cancer Institute, as well as Professor of Medicine at Harvard Medical School.